|1.||Ramana, Kota V: 33 articles (10/2013 - 10/2002)|
|2.||Srivastava, Satish K: 32 articles (10/2013 - 10/2002)|
|3.||Ramasamy, Ravichandran: 16 articles (02/2014 - 02/2002)|
|4.||Petrash, J Mark: 15 articles (06/2015 - 02/2003)|
|5.||Kador, Peter F: 12 articles (02/2014 - 06/2002)|
|6.||Oates, Peter J: 12 articles (04/2010 - 02/2002)|
|7.||Chung, Sookja K: 11 articles (09/2015 - 08/2003)|
|8.||Choi, Jae Sue: 11 articles (06/2015 - 09/2006)|
|9.||Yadav, Umesh C S: 11 articles (06/2013 - 10/2007)|
|10.||Tammali, Ravinder: 11 articles (04/2013 - 10/2006)|
|1.||Diabetic Neuropathies (Diabetic Neuropathy)
09/01/1997 - "Despite numerous attempts over 16 years, the results of aldose reductase inhibitor (ARI) trials for the treatment of diabetic neuropathy have not proven efficacy. "
05/01/2006 - "Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy."
06/01/2001 - "Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy."
09/01/1998 - "[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]."
01/01/1994 - "The clinical efficacy of an aldose reductase (AR) inhibitor in diabetic polyneuropathy depends on its bioavailability at the site(s) of AR in peripheral nerves. "
09/01/2006 - "Aldose reductase (AR) has been implicated in the pathogenesis of diabetic complications, although the clinical efficacy of AR inhibitors has not been clearly proven. "
09/01/2013 - "Therapeutic intervention with aldose reductase inhibitors appears to be promising for major pathological conditions (i.e., long-term diabetic complications and inflammatory pathologies). "
08/01/2003 - "The enzyme aldose reductase (AR) has been implicated in the pathogenesis of some of these diseases and inhibitors of AR (ARIs) were effective in preventing some of the diabetic complications in animal models. "
01/01/2010 - "All analysis of SOMFA model may provide useful information in the design of new aldose reductase inhibitors with improved spectrum of activity for management of diabetic complications."
07/06/1993 - "This assay system may be useful for direct measurement of the level of tissue aldose reductase in conjunction with the evaluation of the efficacy of aldose reductase inhibitors prescribed for the treatment of diabetic complications."
|3.||Peripheral Nervous System Diseases (PNS Diseases)
03/01/2005 - "Although aldose reductase inhibitors (ARIs) have been shown to be effective against diabetic peripheral neuropathy, their effectiveness on diabetic digestive neuropathy remains to be evaluated. "
01/01/2000 - "To assess the efficacy of aldose reductase inhibitors in the prevention, reversal or delay in the progression of diabetic peripheral neuropathy. "
01/01/1996 - "To assess the efficacy of aldose reductase inhibitors in the prevention, reversal or delay in the progression of diabetic peripheral neuropathy. "
12/01/1996 - "A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. "
09/01/2010 - "The purpose of this article was to examine how aldose reductase (AR) inhibitors are used in the prevention and treatment of peripheral neuropathy in diabetes, specifically focusing on efficacy. "
04/01/1983 - "Aldose reductase inhibitors have been effective in the prevention of sugar cataracts. "
04/01/2007 - "The aim of this study was to investigate whether increasing the viscosity of a topical aldose reductase inhibitor suspension increases the lenticular bioavailability of the inhibitor and whether such a formulation can arrest sugar cataract formation. "
03/01/2005 - "The objective of these investigations was to extend our earlier study on the induction of cataracts in diabetic mice, a low aldose reductase (AR) animal model at morphological level. "
01/01/2005 - "Aldose reductase blockers were able to prevent the development of diabetic cataracts in experimental studies, however clinical trials were interrupted due to unclear side effects. "
03/01/2003 - "The present studies provide evidence of significant biochemical changes associated with such cataract formation despite very low levels of aldose reductase. "
|5.||Diabetic Retinopathy (Retinopathy, Diabetic)
11/01/1995 - "Aldose reductase inhibitors may be beneficial in ameliorating the similar vascular lesions characteristic of human diabetic retinopathy, though the mechanism remains obscure."
07/25/2015 - "In this study, the compounds isolated from the Caesalpinia pulcherrima, have been examined for its inhibitory effects on aldose reductase (AR), which plays a major role in diabetic retinopathy. "
04/01/2015 - "Studies investigating the associations between aldose reductase (ALR) genetic polymorphisms and diabetic retinopathy (DR) have reported controversial results. "
03/01/2011 - "A detailed analysis of clinical diabetic retinopathy trials of aldose reductase inhibitors is also provided."
04/01/2005 - "The study aimed to determine whether the aldose reductase gene is involved in diabetic retinopathy in the Tunisian population. "
|3.||ONO 2235 (epalrestat)
|3.||Estrogen Replacement Therapy
|5.||Heterologous Transplantation (Xenotransplantation)